Close Menu

NEW YORK (GenomeWeb) – UBS today initiated coverage of Agilent Technologies with a Buy rating and price target of $92; Fluidigm with a Neutral rating and price target of $14; and Qiagen with a Neutral rating and price target of $42.

In a report to investors, UBS analyst Daniel Brennan noted that for Agilent, the investment bank's above-consensus 2019 through 2021 organic revenue forecasts are supported by durable high single-digit growth in pharma along with growth tied to the gas chromatography product cycle in the chemical and energy segment.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.

Sponsored by

This webinar will share the results of comparisons of commercially available nucleic acid amplification tests for use in routine screening of pregnant women for Group B Streptococcus (GBS).

Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

Sponsored by
Thermo Fisher Scientific

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.